Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

China Health Group Inc.
中國醫療集團有限公司

(Carrying on business in Hong Kong as "萬全醫療集團")

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 08225)

VOLUNTARY ANNOUNCEMENT OF CHINA HEALTH GROUP INC. BUSINESS UPDATE

The China Health Group Inc. (the "**Company**") hereby announces that, the "AI-RWS Real-World Study Summit Forum" was successfully held in Shanghai recently, and more than ten AI-driven real-world study (AI-RWS) projects targeting two major high-incidence neuropsychiatric diseases, namely Chinese adolescent mental disorders and Alzheimer's disease with behavioral and psychological symptoms (BPSD), were launched collectively. This marks a crucial step in the Group's strategic layout in the "AI + Clinical Research" track of the Hong Kong stock market, further consolidating its leading position in the industry.

I. Academic and Research System

The forum gathered 40 domestic authoritative experts in the fields of pediatrics, adolescent psychiatry, and geriatric cognitive impairment. Learning from Stanford University and Mayo Clinic, and with reference to the latest evidence-based guidelines of JAMA Psychiatry (2024), a full-cycle closed-loop research system of "AI intelligent typing – optimization of personalized treatment pathways – dynamic prediction of efficacy and safety – early warning of recurrence risk" has been constructed. This system integrates technologies such as NLP and deep learning, as well as multi-dimensional real-world data, and will provide high-level real-world evidence (RWE) suitable for the characteristics of the Chinese population for the two diseases.

II. Core Track Layout and Key Products

100-Billion-Yuan Adolescent Mental Disorder Track: Targeting over 30 million patients in China, an AI-RWS cohort study covering more than 10,000 patients from over 30 institutions in 15 cities nationwide has been launched. Simultaneously, the Xixin Adolescent Real-World Study – a study exploring comorbidities of Xixin six-combination or sequential therapy – is being conducted, involving Xixin new drug combinations such as Xixin A, Xixin Ai, Xixin Li, Xixin An, Xixin She, and Xixin Le. Through independent AI algorithms, three major corporate innovative services are realized: first, optimizing children's mental health research protocols; second, conducting research on comorbidities of new drug combinations; third, realizing future prediction of disease courses. Relevant results will support the iteration of clinical diagnosis and treatment standards and the formulation of medical insurance policies.

Trillion-Yuan Alzheimer's Disease and BPSD Track: The "Star Plan" has been launched to build the largest-scale and longest follow-up period BPSD real-world database in China, planning to include 100,000 patients within five years. It focuses on research such as non-pharmacological interventions and combination therapies, providing key data for innovative drug registration and post-marketing safety re-evaluation, etc.

Core of clinical research in this track: The Group has obtained the exclusive rights in China for clinical research experiments and real-world clinical research of Xienka Microchip Nanoparticles and Xienmei Flash Tablets.

Xienka Microchip Nanoparticles, the core clinical research product in this track, is a globally exclusive formulation covered by national medical insurance and a Grade A recommended product with Level 1 evidence for the treatment of mild to moderate dementia. Adopting VSMART patented technology, it can solve swallowing difficulties, be mixed with liquid food, avoid gastrointestinal reactions, and its therapeutic effect in treating comorbid mental and Parkinson's disorders is superior to other current similar products.

III. Commercialization Path and Future Outlook

The Group adopts a diversified funding model of "co-construction with research hospitals + pharmaceutical company commissions + government special projects + insurance co-payment", with the expected value of a single project ranging from tens of millions to hundreds of millions of yuan. Relying on platforms such as Boao (Hainan) and Hengqin, it can shorten the Phase IV clinical research time of partners by more than 30%. Research results and core product advantages are simultaneously aligned with the relevant strategies of the National Health Commission, enjoying the advantage of policy dividends.

In the future, the Group will focus on AI-RWS research and the development of doctor intelligent agents, with core layout in three areas: Xixin Mental Health Brand, Xien Neuro Brand, and Baimin Allergic Reaction Brand, committed to becoming a global leader in this field. It will accelerate the transformation to AI-driven clinical research services to create more outstanding value returns for shareholders.

By Order of the Board
China Health Group Inc.
GUO Xia
Chairman

Hong Kong, 15 September 2025

As at the date hereof, the Board comprises two executive Directors, being Mr. GUO Xia, Mr. Raymond Guo; two non-executive Directors, being Dr. ZHANG Li and Dr. WANG Dajun Denis; and four independent non-executive Directors, being Dr. NI Binhui, Mr. WU Shuangsi, Dr. GUO Tong and Ms. LIU Na .

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the website of the Stock Exchange at *www.hkexnews.hk* for 7 days from the date of its posting. This announcement will also be posted on the Company’s website at http://www.chgi.net.